Clinical trials examine the safety and effectiveness of new mesothelioma treatments.  Mesothelioma trials are conducted in the hopes of finding better and more effective ways to treat this disease.  Before participating in any trial, a patient should discuss the matter thoroughly with their doctor. 

Every clinical trial will have potential risks and benefits and it is essential that a patient thoroughly understand what to expect.  Some trials are conducted in major cities, while others will require travel for treatment and routine tests.  In addition, eligibility for trials will depend upon many factors such as your current and prior treatment.  Your physician will be able to advise a patient on the best trial for their symptoms. 

While there is still no cure for mesothelioma, clinical trials are one of the best ways to test new drugs, treatments and procedures in the fight against this disease.

• Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
  
  The purpose of this study is to investigate whether or not video-assisted surgery to remove tissue layer covering the inside of the chest cavity may be effective in treating pleural effusion and cause less damage to normal tissue.
  
  
• Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
  
  The purpose of this study is to determine if bortezomib would be effective in stopping the growth of tumor cells by blocking blood flow to the tumor. This phase II trail's main purpose is to study the side affects of bortezomib and how well giving bortezomib and cisplatin in combination as a first-line therapy in treating patients with malignant mesothelioma.
  
  
• Sorafenib in Treating Patients With Malignant Mesothelioma
  
  The purpose of this phase II trail is to study how well sorafenib works in treating patients. Sorafenib may be effective in stopping the growth of tumor cells by blocking blood flow to the tumor and some of the enzymes needed for cell growth.
  
  
• Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
  
  The purpose of this phase III trial is to study whether the addition of bevacizumab to the standard chemotherapy treatment of MPM would increase overall survival and quality of life beyond that achieved with chemotherapy alone.
  
  
• NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
  The purpose of this phase III trial is to document the efficacy of NGR015 administered in low doses weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
  
  
• A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab)
  Multicenter, open phase 2 study on patients with malignant mesothelioma. Standardly, 4 to 6 cycles of palliative chemotherapy, platinum in combination with pemetrexed, are given. Despite of this treatment, median survival is poor (9-12 months). By combining conventional cytotoxic agents with a novel agent, hopefully treatment and survival can be approved. Cetuximab or Erbitux is a monoclonal antibody against the EGFR (Epidermal Growth Factor Receptor). By blocking the receptor, it interferes with cel growth and division. Most mesothelioma show a strong expression of the EGFR protein. Apart from that, Cetuximab also has antibody-dependent cell-mediated cytotoxicity (ADCC).

  In this trial, patients will be treated with standard chemotherapy, combined with Cetuximab weekly. After a maximum of 6 cycles of chemotherapy, administration of Cetuximab will be continued until disease progression. Every 6 weeks, a CT scan will be done to evaluate therapy. Most common side effect of Cetuximab is acneiform rash.

  The translation research program consists of the determination of EGFR- and K-Ras mutations on the tumor tissue and the correlation with outcome.

  In the first part of the trial, 18 patients will be included. After a positive interim analysis, a total of 43 patients will be included.
  
  

• Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
  The purpose of this international, randomized, double-blind, placebo-controled study is to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).
  
  
• Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
  The purpose of this phase I and phase II study is to evaluate full-dose cisplatin and pemetrexed combined with CBP501 (at the MTD determined in the phase I part) in previously untreated, unresectable malignant pleural mesothelioma patients.
  
  
• Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
  This phase I trial is studying the side effects and best dose of immunotoxin therapy when given together with pemetrexed and cisplatin in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.
  
• Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
  The purpose of this study is to evaluate the safety and effectiveness of tumor cell vaccines given with ISCOMATRIX(Trademark) and celecoxib in the treatment of lung and esophagus cancers.
  
  
• Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
  The purpose of this phase II study is to evaluate the safety and effectiveness of IMC-A12 treatment in patients with mesothelioma who have previously had chemotherapy.
  
  
• Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma
  This is a randomised Phase II clinical trial to assess and compare efficacy and safety profile of cisplatin and pemetrexed against cisplatin and low-dose gemcitabine in long infusion.
  
  
• Intrapleural Gene Transfer for Pleural Mesothelioma (IFN-alpha)
  This research will study how to activate the immune system by using gene transfer. Gene transfer involves inserting a specially designed gene into cancer cells. A gene is a part of the genetic code that instructs the cells of our bodies to produce specific compounds (proteins) important for the makeup or function of the cell. The study hypothesis is that repeated doses of SCH 721015 given over a three day interval would result in gene transfer.
  
  
• Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
  The primary objective of the study is to determine the overall 1 year survival rate of the two combined arms.
  
  
• Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
  The purpose of this study is to investigate what effects, both good and bad, that everolimus has on the cancer. Everolimus works by blocking a protein that helps the cancer grow. The goal of this clinical research study is to learn if the study drug everolimus can shrink or slow the growth of mesothelioma. The safety of this drug will also be studied. The patients' physical state, changes in the size of the tumor, and laboratory findings taken during the study will help us decide if everolimus is safe and effective.
  
  
• Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
  The primary objective of this study is to determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. The secondary objectives of this study are to explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: histologic analysis of biopsy tissue, by non-invasive assessments of tumor vascularity performed before, during and after treatment, electron microscopy analysis of endothelial cell architecture after patient treatment with imatinib mesylate, to explore the effects of cisplatin, imatinib mesylate, and pemetrexed on surrogate markers in serum. Also, to assess the rate of response to therapy, to determine the doses of the combination regimen of cisplatin, imatinib mesylate, and pemetrexed that enables de-phosphorylation of platelet derived growth factor receptor (PDGF-R) on malignant mesothelioma tumor cells, and to determine the pharmacokinetic interaction between agents in this combination regimen.
  
  
• Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
  Despite the best surgical efforts, complete removal of mesothelioma is possible in approximately 30% of the patients. When surgical removal is complete, chemotherapy followed by radiation therapy is recommended as an effort to improve control over the cancer and survival. This combination of treatments is called TRIMODALITY therapy. Unfortunately, the chances for the tumor coming back after TRIMODALITY therapy remains high. When surgical removal is not complete or not possible, some patients may receive chemo and/or radiation therapy to achieve control over the cancer, but the chances of tumor to growth again remains high and the chances of long term survival remains low.

  The combination of Pemetrexed (Alimta) with Cisplatin has been approved as one of the standard chemotherapy drug combinations for the treatment in advanced Malignant Pleural Mesothelioma, and there is likely a group of patients who may benefit and potentially be cured by this therapy. In an effort to achieve a better chance of complete removal of the cancer and long term survival, the investigators are interested in using this drug combination of Pemetrexed + Cisplatin before surgery and offer radiation therapy after surgery.
  

• Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
  The purpose of This phase I trial is to study the side effects and best dose of sunitinib when given together with hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy.
  
  
• A Study in Non Small Cell Lung Cancer
  LY2603618 is a potent and selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (Chk1). It is being developed as a chemotherapeutic-enhancing agent in the treatment of cancer. Ongoing Phase 1 studies have shown the feasibility of combining LY2603618 with either gemcitabine or pemetrexed. The objective of this study is to find the dose of LY2603618 that can be safely combined with standard doses of pemetrexed and cisplatin and to test if this triplet offers a significant improvement in progression-free survival in patients with Stage IV nonsquamous non-small cell lung cancer (NSCLC) in the first-line of palliative treatment.
  
  
• Trimodality Therapy for Malignant Pleural Mesothelioma
  The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is still controversial. The selection criterion to perform either Extrapleural Pneumonectomy (EPP) or Pleurectomy/Decortication (P/D) is dependent not only on the cardio-pulmonary status of the patient, tumor stage and intraoperative findings but also on surgeons' decision and philosophy. There are no established guidelines. Radical Pleurectomy (RP) competes against EPP as surgical therapy modality. Both surgical approaches are cytoreductive treatment options. The aim is to remove all gross disease and to achieve macroscopic complete resection.

  Originally P/D was a palliative option for controlling pleural effusion. But lung-sparing surgery for MPM seems to be an alternative to patients unsuitable or unwilling to undergo EPP in a multimodality therapy concept. Most studies evaluating multimodality therapies for MPM are based on retrospective analyses and their interpretation is difficult because of inhomogeneous patient groups studied.

  The aim of our study was to analyze the feasibility and results of RP as surgical therapy modality in a standardized trimodality therapy concept.
  

• Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
  Study chemotherapy will consist of four treatments with Velcade (days 1, 4, 15, and 18) and two treatments with Eloxatin(days 4 and 18). Patients will be undergo standard of care blood work and Quality of Life (QOL) questionnaires at each visit and will be have repeat CT scans performed to assess tumor response every 2 cycles (8 weeks). Each patient will be allowed to receive a maximum of 6 cycles of therapy. Following discontinuation of treatment due to disease progression or completion of therapy, patient's will be followed for survival, QOL assessments, and tumor assessments every 3 months (or as clinically indicated) for the first year and every 3 months thereafter for a maximum of 5 years.
  
  
• Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
  The purpose of this study is to determine safety and toxicity for the combination of Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma. This is a single-center, open-label, single-arm Phase I dose-escalation trial. Patients will be evaluated with complete history and physical as well as laboratory studies (complete blood count, metabolic panel, liver function tests), biopsy, and imaging of all sites of measurable disease. This study will be conducted over the course of 3 years.
  
  
• Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
  This phase II trial's purpose is to study how well everolimus works in treating patients with pleural malignant mesothelioma that cannot be removed by surgery.
  
  
• Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
  This research study is looking at mesothelin and osteopontin as diagnostic markers in patients with mesothelioma or atypical hyperplasia.
  
  
• Axitinib in Malignant Mesothelioma (N08CPA)
  The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma.
  
  
• Dasatinib in Resectable Malignant Pleural Mesothelioma
  The primary purpose of this phase I study will be to determine the level of biomarker modulation of p-Src Tyr 419 by induction dasatinib therapy in patients with resectable malignant pleural mesothelioma. Secondary objectives include overall and progression-free survival, tumor radiographic and pathologic response, and safety-toxicity profiles. Exploratory analyses will include additional biomarker evaluation in pre- and post-treatment tumor specimens, and serum/platelet/pleural effusion biomarker modulation.
  
  
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
  This randomized phase I and phase II trial's purpose is to examine the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma.
  
  
• Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
  The purpose of this study is to determine whether the combinaition of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.
  
  
• An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
  This study is a multicentre, open label, non-comparative, two stage phase II trial to assess the activity of ZD1839 (IRESSA) in patients with malignant mesothelioma. Patients will receive trial treatment as first-line therapy, administered continuously once daily until the completion of six 4-week cycles of treatment, disease progression, unacceptable toxicity or withdrawal of consent. Patients continuing to show evidence of response, disease stabilization or clinical benefit from ZD1839 may continue to receive therapy beyond completion of the trail.
  
  
• SU5416 in Treating Patients With Malignant Mesothelioma
  The purpose of this phase II trial is to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma.
  
  
• Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
  This is a Phase I trial to study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.
  
  
• Active Symptom Control With Or Without Chemotherapy In Treating Patients With Malignant Pleural Mesothelioma
  
  The purpose of this randomized phase III trial is to examine active symptom control and chemotherapy to determine how well they work when compared to active symptom control alone in patients with malignant pleural mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and will take place in Leeds General infirmary at Leeds Teaching Hospital NHS Trust in Leeds, UK. 
  
  
• Collecting Tumor Samples From Patients With Gynecological Tumors
  The purpose of this laboratory study to is collect tumor tissue and blood samples from patients with gynecologic tumors
  
  
• Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
  The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.
  
  
• ONCONASE Plus Doxorubicin Versus Doxorubicin Alone for Patients with Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
  
  The purpose of this randomized phase III trial is to see how well doxorubicin alone works when compared to doxorubicin and Onconase in treating patients with malignant mesothelioma.  This trial is being conducted by the NCI and will take place in Indiana, Maryland, Michigan, Minnesota, Missouri, Nebraska, and New  Mexico and other international locations.
  
  
• Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma
  
  The purpose of this randomized phase II trial is to determine how well pemetrexed disodium and gemcitabine work when compared to pemetrexed disodium and carboplatin when treating patients with advanced malignant pleural mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and the North Central Cancer Treatment Group.  It will take place in Connecticut, Delaware, Florida, Georgia, Illinois, India, Iowa, Maryland, Michigan, Minnesota, New Jersey, New York, North Dakota, Ohio, Pennsylvania, South Dakota and Wisconsin.
  
  
• Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
  
  Occupational exposure to asbestos increases the risk of developing lung cancer. The purpose of this study is to develop low-dose computed tomography as a tool to identify the existence of mesothelioma before symptoms occur.  This trial is being conducted by the University Health Network in Toronto and will take place in Ontario, Canada.
  
  
• Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
  
  The purpose of this phase II trial is to see how well dasatinib works when treating patients with previously treated malignant mesothelioma.  This trial is being conducted by the University Health Network in Toronto and will take place in Ontario, Canada.
  
  
• Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
  
  The purpose of this phase II trial is to determine how well pazopanib treats patients with malignant pleural mesothelioma.  This trial is being conducted by the National Cance Institute (NCI) and the North Central Cancer Treatment Group.  It will take place in Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Montana, North Carolina, North Dakota, Ohio, Pennsylvania, South Carolina, South Dakota, Wisconsin, and Wyoming.
  
  
• Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma
  
  The purpose of this phase II trial is to determine how well giving combination chemotherapy with or without surgery and chemoradiotherapy works when treating malignant pleural mesothelioma patients.  This trial is being conducted by the National Cancer Institute (NCI)  and the Case Comprehensive Cancer Center.  It will take place in Ohio.
  
  
• Tomotherapy Treatment for Mesothelioma
  
  Patients who suffer from mesothelioma typically suffer various symptoms including shortness of breath and chest pain. This trial examines the use of new radiation technology (tomotherapy) as a means to aggressively treat mesothelioma. The study will recruit 17 patients to examine their symptoms before and after tomotherapy treatment.  This trial is being conducted by the Alberta Cancer Board and will take place in Alberta Canada.
  
  
• An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
  Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.
  
  
• Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
  
  The purpose of this phase II trial is to study the side effects of bortezomib and how well it works when treating patients with malignant pleural mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and the  Irish Clinical Oncology Research Group.  It will take place in Belgium, Ireland, Netherlands, England, Northern Ireland and Scotland.
  
  
• AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
  
  This phase II trial will examine how effective AZD2171 is at treating malignant mesothelioma that cannot be surgically removed.  This trial is being conducted by the National Cancer Institute (NCI) and the  University of Chicago.  It will take place in California, Illinois, Indiana, Michigan, Pennsylvania, Wisconsin and Ontario, Canada.
  
  
• ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
  
  The purpose of this randomized phase III trial is determining how well doxorubicin works when compared to doxorubicin and Onconase in treating people with malignant mesothelioma.  This trial is being conducted by National Cancer Institute (NCI) and will take place in Indiana, Maryland, Michigan , Minnesota, Missouri, Nebraska, New Mexico, Germany, Italy, and Poland.
  
  
• Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
  
  This phase II tiral is to determine how well giving pemetrexed disodium and cisplatin followed by radiation therapy and surgery works in treating patients with malignant pleural mesothelioma.  This trial is being conducted by the National Cancer Institute and the European Organization for Research and Treatment of Cancer.  It will take place in Belgium, Italy, Netherlands, England and Scotland.
  
  
• Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
  
  The purpose of this phase II trial is to determine how well bortezomib and cisplatin work as a first-line treatment for patients with malignant mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer.  It will take place in England.
  
  
• AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
  
  This phase II trial will examine how well AZD2171 works in treating patients with malignant pleural mesothelioma that is not removable by surgery.  This trial is being conducted by the National Cancer Institute (NCI) and the University of Chicago.  It will take place in California, Illinois, Indiana, Michigan, Pennsylvania, Wisconsin and Ontario, Canada. 
  
  
• PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
  
  The purpose of this phase II trial is to see how well PXD101 works as a second-line therapy when treating patients with malignant mesothelioma of the chest that cannot be removed by surgery.  This trial is being conducted by the National Cancer Institute (NCI) and the California Cancer Consortium.  It will take place in California, and Pennsylvania.
  
  
• Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
  
  The purpose of this randomized phase II trial is to discover how well giving pemetrexed disodium with cisplatin followed by surgery with or without radiation therapy works in treating malignant pleural mesothelioma patients.  This trial is being conducted by the National Cancer Institute (NCI) and the Swiss Group for Clinical Cancer Research.  It will take place in Switzerland.
  
  
• Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
  This study is being conducted to evaluate the overall safety and effectiveness of an investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one that has not been approved by the FDA. Approximately 40 people will be enrolled on this study at the University of Pennsylvania (Main Institution/Coordinating Site) and the University of Chicago (Participating Institution). We expect about 20 subjects to be enrolled at each institution.
  
  
• Combination Gene Transfer and Chemotherapy
  The purpose of this study is to find the safety of combination gene therapy and chemotherapy in patients with malignant pleural mesothelioma. Pleural catheter will be placed first, then pts will receive 2 doses of intrapleural vector followed by front line or second line chemotherapy 4-6 cycles every 21 days.
  
  
• Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
  The purpose of this clinical research study is to find the highest tolerable dose of radiation that can be given directly to the pleura (the outer lining of the lungs) using intensity modulated radiation therapy (IMRT) in patients with malignant mesothelioma (MM) who have had a pleurectomy.
  
  
• ChemoFx® PRO - A Post-Market Data Collection Study
  This study will collect patient demographic, oncology history, and physician reported outcome information following the initial round of chemotherapy received after a commercial ChemoFx® Final Report for the generation of hypotheses of potential patient cohorts for further sub-studies.
  
  
• Dendritic Cell Vaccination for Patients With Solid Tumors
  The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) - engineered to express the WT1 protein - in patients with limited spread metastatic solid tumors, i.e. breast cancers, glioblastoma grade IV, sarcomas, malignant mesothelioma and colorectal tumors. Based on the results of our previously performed phase I study with autologous WT1 mRNA-transfected DC, the investigators hypothesize that the vaccination with DC will be well-tolerated and will result in an increase in WT1-specific CD8+ T cell responses.
  
  
• Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
  The purpose of this randomized phase II trial is to study how well pemetrexed disodium or observation works in treating patients with malignant pleural mesothelioma without progressive disease after first-line chemotherapy.
  
  
• A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
  The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered. The study also aims to understand how doctors may have used the results of the ChemoFx® to treat patients with cancer.
  
  
• A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma (ADAM)
  The purpose of this study is to examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
  
  
• Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
  This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.
  
  
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
  The purpose of this study is to evaluate the safety and effectiveness of tumor cell vaccines in combination with cyclophosphamide and celecoxib in patients with cancers involving the chest.
  
  
• Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
  For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and toxicity of standard chemotherapy +/-pleurectomy/decortication followed by IMRT to the pleura in patients with malignant pleural mesothelioma.
  
  
• Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Mediastinal or Chest Wall Neoplasms, or Lung Metastases From Cancers of Non-Thoracic Origin
  This study is collecting and examining tissue, blood, and urine samples from patients with non-small cell lung cancer, esophageal cancer, malignant pleural mesothelioma, mediastinal or chest wall neoplasms, or lung metastases from cancers of non-thoracic origin.
  
  
• Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
  The purpose of this study is to test a Wilms Tumor-1 (WT1) vaccine to see if it delays or prevents mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth. Mesothelioma tumors generally have high levels of WT1.
  
  
• Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS)
  The purpose of this study is to determine whether the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.
  
  
• Short Neoadjuvant Hemithoracic IMRT for MPMShort Neoadjuvant Hemithoracic IMRT for MPM
  This study will look at whether giving a short intense course of chest radiation just prior to surgery will sterilize these tumour cells and thus, avoid or reduce contamination of the areas outside the chest cavity. The investigators hypothesize that short neoadjuvant (pre-operative) hemithoracic RT, followed by immediate planned extrapleural pneumonectomy (EPP) (+/- adjuvant chemotherapy) will reduce the risk of intra-operative seeding and reduce the incidence of distant metastatic disease.
  
  
• Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (HOPE)
  The purpose of this clinical trial is to study the quality of life and survivorship care in patients undergoing surgery and chemotherapy for peritoneal surface malignancies.
  
  
• Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
  Determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin.
  
  
• B-Receptor Signaling in Cardiomyopathy
  We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.
  
  
• Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
  Non-small cell lung cancer (NSCLC) is the most deadly cancer in the world. NSCLC annually causes 150,000 deaths in the US and greater than 1 million worldwide. The standard treatment for early stage NSCLC is lobectomy with lymphadenectomy. However, many patients are poor operative candidates or decline surgery. An emerging alternative is Stereotactic Body Radiation Therapy (SBRT). Mounting evidence from Phase I/II studies demonstrates that SBRT offers excellent local control. Most SBRT trials focused on small, peripheral tumors in inoperable patients. Increasingly, clinical trials study SBRT in operable patients, often with larger, central tumors.

  Using clinical staging, a significant proportion of patients harbor occult nodal metastases when undergoing SBRT to the primary tumor alone. Subgroups of patients carry even higher risk of nodal metastases. These nodal metastases frequently would be removed by surgical intervention. However, SBRT, at present, is only directed at the primary tumor, potentially leading to regional failures in otherwise curable patients. To increase the effectiveness of SBRT for lung tumors, the next logical step is to explore whether the highest risk areas of disease spread can be identified and targeted. Regional failure could be reduced and outcome improved in a significant proportion of patients treated with SBRT if the primary nodal drainage (PND) were identified, targeted and treated in addition to the primary tumor.

  We propose to conduct a study to determine how well water soluble iodinated contrast material when injected directly into the tumor can be visualized on CT scan and integrated into radiation therapy treatment planning.
  
  

• Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
  This laboratory study is looking at previously collected and stored tissue samples from patients previously enrolled in a completed National Cancer Institute clinical trial.
  
  
• Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
  This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.
  
  
• Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
  The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this combined modality approach in patients with mesothelioma; to evaluate cisplatin effects by determining where it goes and how it is excreted in the body from the collection of tissues and cisplatin samples; to collect and analyze discarded samples of mesothelioma tumor during surgery to help determine the genetic make-up of the disease.
  
  
• N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy (NAC-PNP)
  In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin.
  
  
• FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer
  This phase I trial is studying the side effects and best dose of FR901228 when given together with flavopiridol in treating patients with advanced lung, esophageal, or pleural cancer.
  


• Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
  The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be determined based on DLTs occurring during the first treatment cycle. Pharmacokinetics of the triplet combination will be assessed during the phase I part of the trial.

  The phase II part will evaluate full-dose cisplatin and pemetrexed combined with CBP501 (at the MTD determined in the phase I part) in previously untreated, unresectable malignant pleural mesothelioma patients. Patients will be randomized in a 2 : 1 ratio to pemetrexed, cisplatin and CBP501 (Arm A) or to pemetrexed and cisplatin (Arm B); randomization will be stratified according to histology and performance status.
  

• Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
  
  This phase II trial is trying to determine how effective antineoplaston therapy is in treating patients with advanced mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and Burzynski Research Institute.  It will take place in Texas.
  
  
• Trial of Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients
  
  The objective of this trial is to determine the maximum tolerated does of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma.  This trial is being conducted by the M.D. Anderson Cancer Center and will take place in Texas.
  
  
• Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
  
  The purpose of this phase II trial is to determine how well sunitinib works when treating patients with advanced malignant mesothelioma of the pleura.  This trial is being conducted by the National Cancer Institute and the National Cancer Institute of Canada.  It will take place in Alberta, British Columbia, and Ontario, Canada.
  
  
• Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, or Malignant Pleural Mesothelioma
  
  The purpose of this study is to collect and examine tissue, blood and urine samples from patients who have non-small cell lung cancer, esophageal cancer, or malignant pleural mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and will take place in Maryland.
  
  
• Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
  
  The objective of this randomized clinical trial is to determine how well a combination of chemotherapy, surgery, and radiation therapy work when compared to chemotherapy alone in treating patients with mesothelioma that can be removed by surgery.  This trial is being conducted by the National Cancer Institute (NCI) and the Institute of Cancer Research, United Kingdom.  It will take place in England.
  
  
• Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastic Malignant Pleural Mesothelioma (NGR010)
  
  The purpose of this trial is to record the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.  This trial is being conducted by MolMed S.p.A. and will take place in Italy.
  
  
• Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
  
  The purpose of this study is to estimate the time of cancer progression in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab.  This trial is being conducted by the University of Texas, Southwestern Medical Center and will take place in Texas.
  
• Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma
  
  The purpose of this study is to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug, suberoylanilide hydroxamic acid in treating advanced malignant pleural mesothelioma.  This trial is being conducted by Merck and will take place in Colorado, Georgia, illinois, Maryland, Minnesota, Missouri, New York, Ohio, Pennsylvania, Belgium, Brazil, Quebec, Chile, Germany, Italy, Mexico, Netherlands, New Zealand, Norway, Spain, Sweden, Turkey and Hertfordshire, England.
  
  
• Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma
  
  The objection of this phase II trial is to test the effectiveness of Neoadjuvant Chemotherapy with Pemetrexed plus Cisplatin followed by Surgery and Radiotherapy in patients with Malignant Pleural Mesothelioma state I-III.  This trial is being conducted by Eli Lilly and Company and will take place in Italy.
  
  
• Dendritic Cell-Based Immunotherapy in Mesothelioma
  
  The purpose of this study is to examine the feasibility and safety of a clinical trial using autologous DC as a therapeutic adjuvant for the treatment of malignant pleural mesothelioma.  this trial is being conducted by the Erasmus Medical Center and will take place in Netherlands, Zuid-Holland. 
  
  
• Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma (PMR-MM-002)
  
  Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients. Because pre-clinical data in mice had shown that better results were obtained when regulatory T cells were depleted using low-dosis of cyclophosphamide, ten patients who responded on chemotherapy are selected for DC-treatment in combination with Endoxan.
  
  
• Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) (CBP08-02)
  This is a randomized, open-label, multicenter, phase II study to compare a triplet combination of CBP501, pemetrexed and cisplatin with pemetrexed/cisplatin when administered to patients with locally advanced (stage IIIB with malignant pleural effusion or pericardial effusion) or metastatic (stage IV) non-squamous NSCLC as consecutive i.v. infusions according to a once-every-3-weeks schedule.
  
  
• Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
  
  The primary purpose is to determine antitumor activity with the combination of bevacizumab, pemetrexed and carboplatin.  This trial is being conducted by Isituto Clinico Humanitas and will take place in Milan, italy.
  
  
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
  
  The objective of this phase I trial is to examine the side effects of vaccine therapy and GM-CSF in treating patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma.  This trial is being conducted by the National Cancer Institute (NCI) and the Memorial Sloan-Kettering Cancer Center.  It will take place in New York.
  
  
• Combination Chemotherapy in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases.
  
  The objective of this phase I trial is studying the side effects and best does of decitabine and FR901228 in treating patients with unresectable advanced lung cancer, esophageal cancer, pleural mesothelioma, or lung metastases.  This trial is being conducted by the National Cancer Institute (NCI) and will take place in Maryland.
  
  
• Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
  
  The objective of this study is to evaluate the activity and feasibility of a two drug regimen which is administered partly orally and partly intraveneously in advanced pleural mesothelioma.  This trial is being conducted by the Department of Oncology in Rigshospitalet.  It will take place in Denmark.
  
  
• A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
  
  The objective of this study is to determine the safest doses of an investigational drug called MORAb-009 in patients with pancreatic cancer, mesothelioma, or certain types of ovarian or lung cancer.  This trial is being conducted by Morphotek and will take place in Maryland and Pennsylvania.
  
  
• Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
  
  The objective of this study is to observe the effects of pemetrexed on mesothelioma and lung cancer patients with fluid around their lungs or abdomen.  This trial is being conducted by Eli Lilly and Company and will take place in Denmark, Germany and Spain.
  
  
• Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
  
  The purpose of this phase I trial is to examine the side effects and best dose of flavopiridol in treating patients with metastatic or unresectable refractory solid tumors or hematologic malignancies.  This trial is being conducted by the National Cancer Institute and Dana-Farber Cancer Institute.  It will take place in Massachusetts. 
  
  
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
  
  The purpose of this clinical trial is to determine how well EF5 works to detecting oxygen level and blood vessels in tumor cells of patients who are undergoing photodynamic therapy for intraperitoneal or pleural cancer.  This trial is being conducted by the National Cancer Institute (NCI) and the University of Pennsylvania.  It will take place in Pennsylvania.
  
  
• FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Exophageal, or Pleural Cancer
  
  The objective of this phase I trial is to examine the side effects and best dose of FR901228 when given with flavopiridol in providing treatment to patients with advanced lung, esophageal, or pleural cancer.  This trial is being conducted by the National Cancer Institute (NCI) and will take place in Maryland.
  
  
• Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
  
  This randomized phase III trial is examining how well printed education materials work in helping patients who are completing treatment for stage I, stage II, or stage IIIA breast cancer, colorectal cancer, prostate cancer, or chest cancer to make the transition from cancer patient to cancer survivor easier.  This trial is being conducted by the National Cancer Institute and the Fox Chase Cancer Center CCOP Research Base.  It will take place in Pennsylvania.
  
  
• Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
  
  The purpose of this study is to examine individuals with cancer of the lung, lung lining or esophagus for participation in clinical trials performed by the National Cancer Institute (NCI). The study will also use tissue obtained from disease staging procedures to examine cellular changes in blood and tissue in these cancers.  This trial is being conducted by the National institutese of Health Clinical Center (CC) and the National Cancer Institute (NCI).  It will take place in Maryland.
  
  
• Gene Therapy for Pleural Malignancies
  
  The objective of this phase I study is to determine the safety of two doses of BG00001 on patients with malignant pleural mesothelioma, or pleural effusions who have progressed through at lease one prior therapy or have refused therapy.  This trial is being conducted by the University of Pennsylvania and Biogen Idec.  It will take place in Pennsylvania.
  
  
• Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
  
  The objective of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with pemetrexed and cisplatin for treating advanced solid tumors.  This trial is being conducted by Merck and will take place in Alabama, Nevada, and Texas.
  
  
• Surgery Plus IPHC to Treat Peritoneal Carcinomatosis
  
  The purpose of this study is to determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin.  This trial is being conducted by Wuhan University and will take place in Hubei, China.
  
  
• Study of PXD101 in Patients With Advanced Solid Tumors
  
  The objective of this Phase I dose escalation study of PXD101 is to evaluate the safety, tolerability and pharmacokinetics, and to determine the maximum tolerated dose for once and twice daily dosing in patients with advanced solid tumors.  This trial is being conducted by CuraGen Corporation and will take place in Connecticut, New York, Texas, Denmark and Surrey, United Kingdom.
  
  
• Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
  
  The objective of this study is to understand the safety, anti-tumor activity and how 5-Fluorouracil behaves in the body.  This trial is being conducted by Cura Gen Corporation and will take place in Arizona, Nebraska, and New Hampshire.
  
  
• Electronic Tool to Record Cancer Symptoms in Patients With Advanced Cancer Receiving Palliative Care
  
  The objective of this randomized phase III trial is to examine an electronic tool and determine its effectiveness in recording cancer symptoms in patients with advanced cancer receiving palliative care.  This trial is being conducted by the National Cancer Institute (NCI) and the Swiss Group for Clinical Cancer Research.  It will take place in Switzerland.
  
  
• Rapamycin With Grapefruit Juice for Advanced Malignancies
  
  The objective of this study is to evaluate the highest safe dose of rapamycin when given with a predetermined amount of grapefruit juice.  This trial is being conducted by the University of Chicago and will take place in Illinois.
  
  
• Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
  
  The objective of this study is to determine if combining pemetrexed and bevacizumab could increase the effectiveness of treatment for head and neck cancer.  This trial is being conducted by the University of Pittsburgh, the Eli Lilly and Company, and Genentech and will take place in Pennsylvania.
  
  
• Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Abdominal Cancer
  
  The purpose of this phase I study is to determine the safety of continuous hyperthermic peritoneal perfusion with increasing doses of intraperitoneal cisplatin in the treatment of childhood tumors.  This trial is being conducted by the M.D. Anderson Cancer Center and will take place in Texas.
  
  
• Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
  
  The objective of this study is to determine the effectiveness of using oxaliplatin and gemcitabine administered weekly.  This trial is being conducted by the University of California, Irvine and will take place in California.